The fluorescent in situ hybridization probe market size has grown strongly in recent years. It will grow from $1.68 billion in 2025 to $1.8 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to limited availability of fluorescent probes, reliance on conventional single-color FISH, growing awareness of genetic diagnostics, increasing research funding in molecular biology, adoption of fluorescence microscopy.
The fluorescent in situ hybridization probe market size is expected to see strong growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to development of multiplex and combinatorial barcoded probes, rising applications in personalized medicine, expansion of pharmaceutical and biotechnology research, increasing regulatory compliance and standardization, integration with ai-driven image analysis and data analytics. Major trends in the forecast period include rising adoption of fish probes in clinical diagnostics, expansion of multiplex and high-throughput screening techniques, increasing use in genetic and agricultural research, integration with advanced imaging and analysis tools, focus on custom probe development for personalized medicine.
The growing adoption of personalized medicine is expected to drive the growth of the fluorescent in situ hybridization probe market in the coming years. Personalized medicine is a healthcare approach that utilizes information about an individual’s genetic makeup and lifestyle environment to customize medical treatments and care to their specific requirements. The increasing uptake of personalized medicine is driven by patient preference for health technologies that deliver real-time monitoring and treatment strategies tailored to unique biological characteristics. Fluorescent in situ hybridization (FISH) probes support personalized medicine by enabling the accurate identification of genetic abnormalities at the chromosomal level, thereby informing individualized therapeutic decisions based on a patient’s distinct genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases in 2023, compared with six approvals in 2022. Therefore, the increasing adoption of personalized medicine is fueling the growth of the fluorescent in situ hybridization probe market.
Major companies operating in the fluorescent in situ hybridization probe market are increasingly emphasizing strategic collaborations to gain access to new markets, technologies, and specialized expertise that may be challenging or costly to develop independently. Strategic collaboration refers to a structured partnership between two or more organizations that combine their complementary strengths and resources to achieve shared long-term objectives and mutual benefits. For instance, in April 2025, Empire Genomics, a US-based molecular diagnostics company, partnered with BioDot, a US-based provider of precision dispensing automation, to introduce the BDot Probe Line. The BDot Probe Line delivers a differentiated offering by providing FISH probes that are pre-optimized for automated platforms, addressing a critical challenge faced by clinical cytogenetics and molecular pathology laboratories. These probes are engineered for direct use without manual modification, ensuring seamless compatibility with the BioDot CellWriter S system. This advancement minimizes technician intervention, streamlines laboratory workflows, and reduces turnaround times. The initial BDot Probe Panels support FISH analysis across a broad range of hematologic malignancies, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and other common blood-related conditions.
In April 2025, BioDot Inc., a US-based technology company, also collaborated with Empire Genomics LLC to further enhance automation within cytogenetic and molecular diagnostic workflows. Through this partnership, BioDot and Empire Genomics seek to optimize laboratory operations by integrating the CellWriter S automated platform with pre-optimized hematology probe panels, delivering improved precision, reduced hands-on time, and greater workflow consistency, thereby advancing the efficiency and accuracy of genetic analysis. Empire Genomics LLC is a US-based healthcare technology company that specializes in the development of molecular diagnostic solutions, including FISH probes for clinical research and genetic testing.
Major companies operating in the fluorescent in situ hybridization probe market are Thermo Fisher Scientific Inc., Abbott Laboratories, Oxford Gene Technology IP Limited, Sigma-Aldrich Co. LLC, Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Leica Biosystems Nussloch GmbH, Biocare Medical LLC, Enzo Biochem Inc., LGC Biosearch Technologies, ZytoVision GmbH, Creative Biolabs Inc., Empire Genomics LLC, MetaSystems GmbH, Abnova Corporation, Mirus Bio LLC, Genemed Biotechnologies Inc., Molecular Instruments Inc., Cytocell Technologies Limited.
North America was the largest region in the fluorescent in situ hybridization probe market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluorescent in situ hybridization probe market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fluorescent in situ hybridization probe market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the FISH probe market by increasing costs for imported fluorescent dyes, probe synthesis equipment, and advanced imaging instruments. Segments such as multiplex probes and high-throughput screening probes are most impacted, with Asia-Pacific regions including China and India facing notable import duties. While tariffs have increased production costs and slowed procurement in some regions, they have also encouraged local manufacturing, innovation in probe synthesis technologies, and development of cost-efficient alternatives.
The fluorescent in situ hybridization probe market research report is one of a series of new reports that provides fluorescent in situ hybridization probe market statistics, including fluorescent in situ hybridization probe industry global market size, regional shares, competitors with a fluorescent in situ hybridization probe market share, detailed fluorescent in situ hybridization probe market segments, market trends and opportunities, and any further data you may need to thrive in the fluorescent in situ hybridization probe industry. This fluorescent in situ hybridization probe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A fluorescent in situ hybridization (FISH) probe is a short sequence of single-stranded DNA or RNA labeled with a fluorescent dye, designed to bind (hybridize) to a specific complementary DNA or RNA sequence within a cell or tissue sample. This method enables visualization and localization of specific genetic material in chromosomes, nuclei, or tissue sections using a fluorescence microscope.
The primary types of FISH probes include deoxyribonucleic acid (DNA) probes, ribonucleic acid (RNA) probes, and multiplex probes. DNA probes are molecules that carry the genetic instructions essential for the growth, development, functioning, and reproduction of all known living organisms and many viruses. These probes target genes and chromosomes and utilize various technologies, including single-color FISH, multiplex FISH, quantitative FISH, and others. FISH probes are applied in clinical diagnostics, research, agricultural biotechnology, pharmaceutical research, and genetic studies, serving multiple end users such as hospitals and clinics, research laboratories, pharmaceutical companies, and biotechnology firms.
The fluorescent in situ hybridization probe market consists of revenues earned by entities by providing services such as cancer research, genetic disease detection, and drug development. The market value includes the value of related goods sold by the service provider or included within the service offering. The fluorescent in situ hybridization (FISH) probe market also includes sales of fluorescent dyes, hybridization buffers, detection reagents, control slides, and assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The fluorescent in situ hybridization probe market size is expected to see strong growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to development of multiplex and combinatorial barcoded probes, rising applications in personalized medicine, expansion of pharmaceutical and biotechnology research, increasing regulatory compliance and standardization, integration with ai-driven image analysis and data analytics. Major trends in the forecast period include rising adoption of fish probes in clinical diagnostics, expansion of multiplex and high-throughput screening techniques, increasing use in genetic and agricultural research, integration with advanced imaging and analysis tools, focus on custom probe development for personalized medicine.
The growing adoption of personalized medicine is expected to drive the growth of the fluorescent in situ hybridization probe market in the coming years. Personalized medicine is a healthcare approach that utilizes information about an individual’s genetic makeup and lifestyle environment to customize medical treatments and care to their specific requirements. The increasing uptake of personalized medicine is driven by patient preference for health technologies that deliver real-time monitoring and treatment strategies tailored to unique biological characteristics. Fluorescent in situ hybridization (FISH) probes support personalized medicine by enabling the accurate identification of genetic abnormalities at the chromosomal level, thereby informing individualized therapeutic decisions based on a patient’s distinct genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases in 2023, compared with six approvals in 2022. Therefore, the increasing adoption of personalized medicine is fueling the growth of the fluorescent in situ hybridization probe market.
Major companies operating in the fluorescent in situ hybridization probe market are increasingly emphasizing strategic collaborations to gain access to new markets, technologies, and specialized expertise that may be challenging or costly to develop independently. Strategic collaboration refers to a structured partnership between two or more organizations that combine their complementary strengths and resources to achieve shared long-term objectives and mutual benefits. For instance, in April 2025, Empire Genomics, a US-based molecular diagnostics company, partnered with BioDot, a US-based provider of precision dispensing automation, to introduce the BDot Probe Line. The BDot Probe Line delivers a differentiated offering by providing FISH probes that are pre-optimized for automated platforms, addressing a critical challenge faced by clinical cytogenetics and molecular pathology laboratories. These probes are engineered for direct use without manual modification, ensuring seamless compatibility with the BioDot CellWriter S system. This advancement minimizes technician intervention, streamlines laboratory workflows, and reduces turnaround times. The initial BDot Probe Panels support FISH analysis across a broad range of hematologic malignancies, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and other common blood-related conditions.
In April 2025, BioDot Inc., a US-based technology company, also collaborated with Empire Genomics LLC to further enhance automation within cytogenetic and molecular diagnostic workflows. Through this partnership, BioDot and Empire Genomics seek to optimize laboratory operations by integrating the CellWriter S automated platform with pre-optimized hematology probe panels, delivering improved precision, reduced hands-on time, and greater workflow consistency, thereby advancing the efficiency and accuracy of genetic analysis. Empire Genomics LLC is a US-based healthcare technology company that specializes in the development of molecular diagnostic solutions, including FISH probes for clinical research and genetic testing.
Major companies operating in the fluorescent in situ hybridization probe market are Thermo Fisher Scientific Inc., Abbott Laboratories, Oxford Gene Technology IP Limited, Sigma-Aldrich Co. LLC, Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Leica Biosystems Nussloch GmbH, Biocare Medical LLC, Enzo Biochem Inc., LGC Biosearch Technologies, ZytoVision GmbH, Creative Biolabs Inc., Empire Genomics LLC, MetaSystems GmbH, Abnova Corporation, Mirus Bio LLC, Genemed Biotechnologies Inc., Molecular Instruments Inc., Cytocell Technologies Limited.
North America was the largest region in the fluorescent in situ hybridization probe market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluorescent in situ hybridization probe market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fluorescent in situ hybridization probe market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the FISH probe market by increasing costs for imported fluorescent dyes, probe synthesis equipment, and advanced imaging instruments. Segments such as multiplex probes and high-throughput screening probes are most impacted, with Asia-Pacific regions including China and India facing notable import duties. While tariffs have increased production costs and slowed procurement in some regions, they have also encouraged local manufacturing, innovation in probe synthesis technologies, and development of cost-efficient alternatives.
The fluorescent in situ hybridization probe market research report is one of a series of new reports that provides fluorescent in situ hybridization probe market statistics, including fluorescent in situ hybridization probe industry global market size, regional shares, competitors with a fluorescent in situ hybridization probe market share, detailed fluorescent in situ hybridization probe market segments, market trends and opportunities, and any further data you may need to thrive in the fluorescent in situ hybridization probe industry. This fluorescent in situ hybridization probe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A fluorescent in situ hybridization (FISH) probe is a short sequence of single-stranded DNA or RNA labeled with a fluorescent dye, designed to bind (hybridize) to a specific complementary DNA or RNA sequence within a cell or tissue sample. This method enables visualization and localization of specific genetic material in chromosomes, nuclei, or tissue sections using a fluorescence microscope.
The primary types of FISH probes include deoxyribonucleic acid (DNA) probes, ribonucleic acid (RNA) probes, and multiplex probes. DNA probes are molecules that carry the genetic instructions essential for the growth, development, functioning, and reproduction of all known living organisms and many viruses. These probes target genes and chromosomes and utilize various technologies, including single-color FISH, multiplex FISH, quantitative FISH, and others. FISH probes are applied in clinical diagnostics, research, agricultural biotechnology, pharmaceutical research, and genetic studies, serving multiple end users such as hospitals and clinics, research laboratories, pharmaceutical companies, and biotechnology firms.
The fluorescent in situ hybridization probe market consists of revenues earned by entities by providing services such as cancer research, genetic disease detection, and drug development. The market value includes the value of related goods sold by the service provider or included within the service offering. The fluorescent in situ hybridization (FISH) probe market also includes sales of fluorescent dyes, hybridization buffers, detection reagents, control slides, and assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Fluorescent in Situ Hybridization Probe Market Characteristics
3. Fluorescent in Situ Hybridization Probe Market Supply Chain Analysis
4. Global Fluorescent in Situ Hybridization Probe Market Trends and Strategies
5. Fluorescent in Situ Hybridization Probe Market Analysis of End Use Industries
7. Global Fluorescent in Situ Hybridization Probe Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Fluorescent in Situ Hybridization Probe Total Addressable Market (TAM) Analysis for the Market
9. Fluorescent in Situ Hybridization Probe Market Segmentation
10. Fluorescent in Situ Hybridization Probe Market Regional and Country Analysis
11. Asia-Pacific Fluorescent in Situ Hybridization Probe Market
12. China Fluorescent in Situ Hybridization Probe Market
13. India Fluorescent in Situ Hybridization Probe Market
14. Japan Fluorescent in Situ Hybridization Probe Market
15. Australia Fluorescent in Situ Hybridization Probe Market
16. Indonesia Fluorescent in Situ Hybridization Probe Market
17. South Korea Fluorescent in Situ Hybridization Probe Market
18. Taiwan Fluorescent in Situ Hybridization Probe Market
19. South East Asia Fluorescent in Situ Hybridization Probe Market
20. Western Europe Fluorescent in Situ Hybridization Probe Market
21. UK Fluorescent in Situ Hybridization Probe Market
22. Germany Fluorescent in Situ Hybridization Probe Market
23. France Fluorescent in Situ Hybridization Probe Market
24. Italy Fluorescent in Situ Hybridization Probe Market
25. Spain Fluorescent in Situ Hybridization Probe Market
26. Eastern Europe Fluorescent in Situ Hybridization Probe Market
27. Russia Fluorescent in Situ Hybridization Probe Market
28. North America Fluorescent in Situ Hybridization Probe Market
29. USA Fluorescent in Situ Hybridization Probe Market
30. Canada Fluorescent in Situ Hybridization Probe Market
31. South America Fluorescent in Situ Hybridization Probe Market
32. Brazil Fluorescent in Situ Hybridization Probe Market
33. Middle East Fluorescent in Situ Hybridization Probe Market
34. Africa Fluorescent in Situ Hybridization Probe Market
36. Fluorescent in Situ Hybridization Probe Market Competitive Landscape and Company Profiles
37. Fluorescent in Situ Hybridization Probe Market Other Major and Innovative Companies
40. Fluorescent in Situ Hybridization Probe Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Fluorescent In Situ Hybridization Probe Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses fluorescent in situ hybridization probe market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fluorescent in situ hybridization probe? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fluorescent in situ hybridization probe market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Deoxyribonucleic Acid (DNA) Probes; Ribonucleic Acid (RNA) Probes; Multiplex Probes2) By Target: Genes; Chromosomes; Other Targets
3) By Technology: Single-Color Fluorescence In Situ Hybridization (FISH); Multiplex Fluorescence In Situ Hybridization (FISH); Quantitative Fluorescence In Situ Hybridization (FISH); Others Technologies
4) By Application: Clinical Diagnostics; Research Applications; Agricultural Biotechnology; Pharmaceutical Research; Genetic Research
5) By End User: Hospitals And Clinics; Research Laboratories; Pharmaceutical Companies; Biotechnology Companies
Subsegments:
1) By Deoxyribonucleic Acid (DNA) Probes: Centromeric Probes; Telomeric Probes; Whole Chromosome Paint Probes; Locus-Specific Identifier (LSI) Probes; Comparative Genomic Hybridization (CGH) Probes; Gene Fusion Probes2) By Ribonucleic Acid (RNA) Probes: mRNA Probes; Long Non-Coding RNA (lncRNA) Probes; MicroRNA (miRNA) Probes; Single-Molecule RNA FISH Probes (smFISH); Circular RNA (circRNA) Probes; Multiplexed Error-Robust FISH (MERFISH) Probes
3) By Multiplex Probes: Multicolor DNA FISH Probes; Multigene Expression Analysis Probes; High-Throughput Screening Probes; Multiplex smFISH Probes; Combinatorial Barcoded Probes; Simultaneous DNA/RNA Detection Probes
Companies Mentioned: Thermo Fisher Scientific Inc.; Abbott Laboratories; Oxford Gene Technology IP Limited; Sigma-Aldrich Co. LLC; Agilent Technologies Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Leica Biosystems Nussloch GmbH; Biocare Medical LLC; Enzo Biochem Inc.; LGC Biosearch Technologies; ZytoVision GmbH; Creative Biolabs Inc.; Empire Genomics LLC; MetaSystems GmbH; Abnova Corporation; Mirus Bio LLC; Genemed Biotechnologies Inc.; Molecular Instruments Inc.; Cytocell Technologies Limited.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Fluorescent in Situ Hybridization Probe market report include:- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Oxford Gene Technology IP Limited
- Sigma-Aldrich Co. LLC
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Leica Biosystems Nussloch GmbH
- Biocare Medical LLC
- Enzo Biochem Inc.
- LGC Biosearch Technologies
- ZytoVision GmbH
- Creative Biolabs Inc.
- Empire Genomics LLC
- MetaSystems GmbH
- Abnova Corporation
- Mirus Bio LLC
- Genemed Biotechnologies Inc.
- Molecular Instruments Inc.
- Cytocell Technologies Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.8 Billion |
| Forecasted Market Value ( USD | $ 2.39 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
